New drug duo aims to prime immune system before cancer surgery
NCT ID NCT06159621
Summary
This study is testing a combination of two immunotherapy drugs given to patients before they have surgery to remove their HPV-negative head and neck cancer. The main goals are to see if the treatment is safe and to learn how it affects immune cells in the tumor. About 27 patients will receive one or both drugs a few weeks before their planned operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.